拜登行政当局进行的2026年药品价格谈判旨在节省15亿美元的医药援助受益人的自费费用。 
2026 drug price negotiations by the Biden administration aim to save Medicare recipients $1.5 billion on out-of-pocket costs.
拜登政府从2026年开始与制药公司进行新的药品价格谈判,目的是节省15亿美元的医疗保健计划受益者的自费费用,用于治疗糖尿病、心脏病、血癌和其他病症的药品。 The Biden administration's new drug price negotiations with pharmaceutical companies starting in 2026 aim to save Medicare recipients $1.5 billion on out-of-pocket costs for medications treating diabetes, heart disease, blood cancers, and other conditions. 这些节余包括用于血液癌的糖尿病药物亚努维亚减少79%,Imbruvica减少38%。 These savings include a 79% reduction for Januvia, a diabetes drug, and a 38% decrease for Imbruvica, used for blood cancers. 这些数字是指药物在任何折扣或退款之前的费用,而不是病人支付的实际数额。 The figures refer to the drug's cost before any discounts or rebates, not the actual amount paid by patients.
